Recruiting

Hypofractionated Stereotactic Radiosurgery

Sponsor:

UCLA

Code:

NCT06557512

Conditions

Meningioma

Meningioma, Malignant

Recurrent Meningioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Hypofractionated Stereotactic Radiosurgery (SRS)

Magnetic Resonance Imaging (MRI)

Computed Tomography (CT)

Study Details

Brief summary:

This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Hypofractionated stereotactic radiosurgery may be safe, tolerable, and effective in treating patients with grade II or recurrent grade I meningiomas after surgical resection.

Conditions

Meningioma

Meningioma, Malignant

Recurrent Meningioma

Study ID

NCT06557512

Start date

Dec 13, 2024

Status verified date

Aug, 2026

Completion date

Sep 30, 2029

Anticipated

Primary completion date

Sep 30, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age >+ 18 years at time of study entry
  • Ability to understand and the willingness to sign a written informed consent document.
  • Histologic diagnosis of newly diagnosed World Health Organization (WHO) grade 2 or recurrent WHO grade 1 meningioma. With regard to recurrent WHO grade 1 meningioma, participants must present with radiographic evidence of recurrence, and have a histologic diagnosis of WHO grade 1 meningioma at the most recent resection.

\* Note: For participants diagnosed outside of University of California San Francisco (UCSF), re-review of pathology at UCSF is strongly encouraged. Hematoxylin and eosin (H\&E) slides will be reviewed by UCSF pathologists.
  • Participants must have undergone a gross-total surgical resection as deemed by their neurosurgeon (Simpson grade I-III resection), using all available information which can include post-operative MRI, of a meningioma within 180 days of enrollment.
  • Participants must have a pre-operative MRI.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky score of 70 or higher)
  • Participants must have post-operative MRI indicating anatomy suitable for hypofractionated radiosurgery, as reviewed by the Radiation Oncology co-principal investigators (PIs).

Exclusion Criteria:

  • Concurrent participation in another clinical study with an investigational product unless it is an observational (non-interventional) study or the follow-up period of an interventional study.
  • Extensive multifocal (3 or more meningiomas) or metastatic disease.
  • Participants with tumors within 2mm of the optic apparatus or brainstem will be excluded.
  • Participants with another active primary malignancy or history of previous malignancy (except non-melanoma skin cancers, low and intermediate risk prostate cancers, and in situ cancers such as bladder, gastric, colon, cervical/dysplasia, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
  • Female participants who are pregnant.
  • Any underlying medical or psychiatric condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results.
  • Participants with uncontrolled seizures, defined as greater than 3 disabling seizures per day while on anti-epileptic drugs.
  • Participants who have had previous intracranial radiotherapy overlapping with the area that would be targeted for stereotactic radiosurgery by this study.

Study Design

Enrollment

23 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Hypofractionated Stereotactic Radiosurgery (SRS)

Participants undergo hypofractionated stereotactic radiosurgery over 15-30 minutes QD on days 1-5 in the absence of disease progression or unacceptable toxicity.

Interventions

Hypofractionated Stereotactic Radiosurgery (SRS)

Undergo Hypofractionated Stereotactic Radiosurgery

Magnetic Resonance Imaging (MRI)

Undergo MRI

Computed Tomography (CT)

Undergo CT imaging

Primary outcome measure

  • Proportion of participants with reported adverse events [ Time Frame: Up to 1 year ]

Central Contacts and Locations

Central contacts

Francim Aguilar

877-827-3222Francim.Aguilar@ucsf.edu

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Francim Aguilar

Francim.Aguilar@ucsf.edu

877-827-3222cancertrials@ucsf.edu

Principal Investigator:

William Chen, MD

More Information

Sponsor

University of California, San Francisco

Last update posted

Aug 26, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-08-26.